This could quite easily be referred to as the first ever cancer vaccination due to its effectiveness in protecting against liver cancer resulting from hepatitis B infections, which accounts for up to 80% of all liver cancer cases. The hepatitis B vaccination contains surface antigen (HBsAg) proteins meaning that instead of causing a minor hepatitis B infection, the vaccine acts by stimulating the body’s existing immunity against the disease. The vaccine is a 3-time course of injections that can be administered any time after birth, with the 2nd injection due one month after the 1st, and the 3rd injection 5 months after that.
Most patients retain up to 97% immunity after receiving the full 3-time course of injections, with this immunity lasting a lifetime. However, patients should attend screening around 1–2 months after their final vaccination in order to confirm that their body has built up immunity to the disease and, in cases where this immunity is lacking, doctors may advise an additional vaccination.